Khuluza Felix, Kigera Stephen, Heide Lutz
Pharmacy Department, College of Medicine, University of Malawi, Blantyre, Malawi.
Mission for Essential Drugs and Supplies (MEDS), Nairobi, Kenya.
Am J Trop Med Hyg. 2017 May;96(5):1124-1135. doi: 10.4269/ajtmh.16-1008. Epub 2017 May 13.
AbstractSubstandard and falsified antimalarial and antibiotic medicines represent a serious problem for public health, especially in low- and middle-income countries. However, information on the prevalence of poor-quality medicines is limited. In the present study, samples of six antimalarial and six antibiotic medicines were collected from 31 health facilities and drug outlets in southern Malawi. Random sampling was used in the selection of health facilities. For sample collection, an overt approach was used in licensed facilities, and a mystery shopper approach in nonlicensed outlets. One hundred and fifty-five samples were analyzed by visual and physical examination and by rapid prescreening tests, that is, disintegration testing and thin-layer chromatography using the GPHF-Minilab. Fifty-six of the samples were analyzed according to pharmacopeial monographs in a World Health Organization-prequalified quality control laboratory. Seven out-of-specification medicines were identified. One sample was classified as falsified, lacking the declared active ingredients, and containing other active ingredients instead. Three samples were classified as substandard with extreme deviations from the pharmacopeial standards, and three further samples as substandard with nonextreme deviations. Of the substandard medicines, three failed in dissolution testing, two in the assay for the content of the active pharmaceutical ingredient, and one failed in both dissolution testing and assay. Six of the seven out-of-specification medicines were from private facilities. Only one out-of-specification medicine was found within the samples from public and faith-based health facilities. Although the observed presence of substandard and falsified medicines in Malawi requires action, their low prevalence in public and faith-based health facilities is encouraging.
摘要
不合格和伪造的抗疟药及抗生素对公众健康构成严重问题,在低收入和中等收入国家尤为如此。然而,关于劣质药品流行情况的信息有限。在本研究中,从马拉维南部的31家医疗机构和药品销售点收集了六种抗疟药和六种抗生素的样本。在选择医疗机构时采用随机抽样。样本采集方面,在有许可证的机构采用公开方式,在无许可证的销售点采用暗访人员方式。通过外观和物理检查以及快速预筛选测试(即使用GPHF - Minilab进行崩解测试和薄层色谱分析)对155个样本进行了分析。56个样本在世界卫生组织预认证的质量控制实验室按照药典专论进行分析。鉴定出7种不合格药品。一个样本被归类为伪造药品,缺少宣称的活性成分,却含有其他活性成分。三个样本被归类为不合格,与药典标准有极大偏差,另外三个样本为不合格但偏差不极端。在不合格药品中,三个在溶出度测试中不合格,两个在活性药物成分含量测定中不合格,一个在溶出度测试和含量测定中均不合格。7种不合格药品中有6种来自私立机构。在公立和宗教医疗机构的样本中仅发现一种不合格药品。尽管在马拉维观察到存在不合格和伪造药品的情况需要采取行动,但它们在公立和宗教医疗机构中的低流行率令人鼓舞。